Wellington S, Nag PP, Michalska K, et al. A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nature Chem Biol. 2017;13(9):943-950.
McCarren P, Over B, Artusson P, et al. Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. J Medicinal Chem. 2014;57(6):2746-2754.
Fang C, D’Souza B, Thompson CF, et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Medicinal Chem Lett. 2014;5(12):1308-1312.
McCarren P, Springer C, Whitehead L. An investigation into pharmaceutically relevant mutagenicity data and the influence on Ames predictive potential. J Cheminformatics. 2011;3(51).
Patrick McCarren, Ph.D.
Patrick McCarren is a computational chemist in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, working in the structural biology and modeling group. McCarren uses protein structure to rationally design better drugs in collaboration with chemists and biologists, using computational methods and creative thinking.
Prior to joining the Broad Institute in 2012, McCarren was a postdoctoral fellow in the computer-aided drug discovery group at Novartis. He holds a Ph.D. in computational chemistry from the University of California-Los Angeles working with Kendall N. Houk, as well as bachelor’s degrees in chemistry and physics, with a minor in computer science, from Ohio State University, where he worked with Christopher M. Hadad and Todd Lowary on carbohydrate synthesis and modeling. While at UCLA, he was awarded an NIH Chemistry-Biology Interface Predoctoral Training fellowship and interned in computational chemistry at Pfizer in La Jolla, CA.
Contact Patrick McCarren via email at firstname.lastname@example.org.